Latest Articles

Publication Date
Macrophages in endometriosis: key roles and emerging therapeutic opportunities-a narrative review.

Endometriosis is a chronic gynecological disorder affecting approximately 10% of women of reproductive age. It commonly presents with pelvic pain, dysmenorrhea, and infertility, imposing substantial physical, psychological, and social burdens. …

Published: Oct. 21, 2025, midnight
Integrative transcriptomic analysis identifies shared EndMT-related gene signatures in endometriosis and recurrent miscarriage.

Endometriosis (EMs) and recurrent miscarriage (RM) represent major reproductive health challenges. This study investigates the involvement of endothelial-mesenchymal transition (EndMT) in these conditions through integrative bioinformatics analysis, focusing on the …

Published: Oct. 21, 2025, midnight
'En bloc' peritoneal mesometrial resection (PMMR) and pelvic targeted compartmental lymphadenectomy (TCL) for management of patients with endometrial cancer - feasibility and safety study of a 'new kid on the block' in robotic surgery.

Robotic Peritoneal Mesometrial Resection and Targeted Compartmental Lymphadenectomy (PMMR + TCL) is a procedure following Cancer Field Surgery concept for endometrial cancer (EC), enabling superior locoregional control without adjuvant irradiation. …

Published: Oct. 21, 2025, midnight
Pro-endometriosis macrophage release of IL-33 is key for endometriosis pain and lesion formation.

Endometriosis is a painful gynecological inflammatory disease affecting up to 10% of females. When released by sensory neurons, calcitonin gene-related peptide (CGRP) shapes immunity, a process known as neuroimmune communication. …

Published: Oct. 21, 2025, midnight
What If We Took Endometriosis as Seriously as We Take Diabetes? - Women's eNews

What If We Took Endometriosis as Seriously as We Take Diabetes? Women's eNews

Published: Oct. 20, 2025, 6:42 p.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.

Chronic pain is a widespread condition affecting millions globally, placing significant strain on healthcare systems, as evidenced by the current opioid crisis. Despite advances in pain management, conventional treatments often …

Published: Oct. 18, 2025, midnight
Could endometriosis be diagnosed with a simple test? - pharmaphorum

Could endometriosis be diagnosed with a simple test? pharmaphorum

Published: Oct. 17, 2025, 1:07 p.m.
Dylan Sprouse Rates Barbara Palvin's VS Fashion Show Outfits (Excl) - Us Weekly

Dylan Sprouse Rates Barbara Palvin's VS Fashion Show Outfits (Excl) Us Weekly

Published: Oct. 16, 2025, 5:35 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!